ReviewMolecular interventions2007
Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?
Review in Molecular interventions, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Intracrine and myotrophic roles of 5α-reductase and androgens: a review.Medicine and science in sports and exercise · 2012Pooled it
- Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.The Journal of urology · 2011Trial
- Selective androgen receptor modulators: a critical appraisal.Frontiers in endocrinology · 2025Review
- The Current Landscape of Pharmacotherapies for Sarcopenia.Drugs & aging · 2024Article
- Selective androgen receptor modulators: the future of androgen therapy?Translational andrology and urology · 2020Review
- Development of selective androgen receptor modulators (SARMs).Molecular and cellular endocrinology · 2018Review
- The long and winding road for selective androgen receptor modulators.British journal of clinical pharmacology · 2017Article
- Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.Endocrine reviews · 2014Review
- Sex hormones, aging, and Alzheimer's disease.Frontiers in bioscience (Elite edition) · 2012Review
- 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate.American journal of physiology. Endocrinology and metabolism · 2011Article
- Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140.ACS medicinal chemistry letters · 2011Article
- Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.The Journal of steroid biochemistry and molecular biology · 2010Article
- New selective estrogen and androgen receptor modulators.Current opinion in rheumatology · 2009Review
- Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.Prostate cancer and prostatic diseases · 2009Review
- Pharmacology of anabolic steroids.British journal of pharmacology · 2008Review
- Sarcopenia: diagnosis and treatment.The journal of nutrition, health & agingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Selective Androgen Receptor Modulators (SARMs) are a novel class of AR ligands that possess tissue-selective pharmacological activities. SARMs of various chemical structures have been discovered and characterized, and lead compounds with much improved specificity for AR, in vivo pharmacokinetic profiles, and higher degree of tissue selectivity have entered clinical development, and are expected to dramatically expand the clinical applications of androgens. With the rapid progress in SARM discovery and increasing demand for mechanism-based drug design, more and more research efforts have been devoted to the mechanisms of action of the observed tissue selectivity of SARMs. There is increasing enthusiasm in adapting the molecular mechanisms of action from SERM research to the SARM field; however, is the SARM story really so complicated? The tissue-specific expression of 5alpha-reductase might provide a simple explanation for this puzzle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.